Study ID: TV50717-CNS-30081 | 2019-001807-19

Study Title

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Teva Identifier

TV50717-CNS-30081 | 2019-001807-19

ClinicalTrials.gov Identifier

NCT04200352

Study Status

Recruiting

Trial Condition(s)

Cerebral Palsy, Dyskinetic

Interventions

Drug: TEV-50717

EudractCT Number

2019-001807-19

Study Description

Study TV50717-CNS-30081 is a 55-week study in which patients who have successfully completed the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study.

The primary objective of this study is to evaluate the safety and tolerability of long-term therapy with TEV-50717 in children and adolescents with DCP.

The secondary objective of this study is to evaluate the efficacy of long-term therapy with TEV-50717 in reducing the severity of DCP.


neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

6 Years to 18 Years

Trial Duration

February 4, 2020 - August 19, 2023

Phase

Phase 3

Study Type

Interventional


Location - Where to Participate

You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.

Contact us by location

Find out more